A diary of what
actually works.
Independent, evidence-led reviews of the GLP-1s, peptides, infusions and procedures re-shaping how women age — by clinicians who actually read the studies.
“The Tirzepatide diaries: nine months, four women, one drug.”
in glow.
Retatrutide enters Phase III — and the data is louder than Mounjaro's.
Signal, evidence quality, cost, and what to ignore this week.
BPC-157 oral capsules: stop wasting your money.
Signal, evidence quality, cost, and what to ignore this week.
The exosome facial, ranked against $200 of CeraVe.
Signal, evidence quality, cost, and what to ignore this week.
The Cover Review
May 2026 · A 12-minute read
Tirzepatide, after the hype.
We followed four women across nine months, three doses and twelve panels. The results are spectacular — and so are the parts no one will talk about.
The Index
142 reviews · Updated weekly
Semaglutide vs. Tirzepatide: a 36-week head-to-head.
Mean BMI loss, lean-mass preservation, lipid panels and the side-effect curve nobody charts honestly.
Epitalon: the longevity peptide that won't quit the headlines.
Soviet research, modern protocols, and what the telomere data actually shows when you read past the abstract.
Polynucleotide salmon DNA injectables, audited.
A 12-week dermatology trial across three London clinics. Texture wins; firmness shrugs.
The case for early HRT — and the studies that quietly buried the WHI.
CJC-1295 / Ipamorelin: the growth-hormone stack, demystified.
Tretinoin at 0.025%, every other night, for ten years.
The Glow Index
Q2 2026 standings · By Glow Verdict score